FULCHealthcareMicro-Cap

Fulcrum Therapeutics, Inc. Insider Trading Activity

Every SEC Form 4 insider transaction reported for Fulcrum Therapeutics, Inc. (FULC), sourced directly from SEC EDGAR and updated as new filings are accepted.

Last updated:

Quick Answer

Are FULC insiders buying or selling?

Fulcrum Therapeutics, Inc. insiders reported 18 open-market buys ($51.6M) and 50 sells ($66.7M) across 68 Form 4 filings — a net selling position of $15.1M.

Source: SEC EDGAR Form 4

Key Statistics (as of Jul 21, 2026)

Total Form 4 filings
68
SEC EDGAR
Insider filers
20
Insider buys (18)
$51.6M
Insider sells (50)
$66.7M

Insider sentiment

Net selling

Net insider flow of $15.1M in net selling. 2 insider buys in the last 90 days.

Recent FULC insider transactions

DateInsiderRoleTypeSharesPriceValue
Jul 21, 2026Kevin Tang10% OwnerPurchase167.6K$3.55$594.7K
Jul 15, 2026Kevin Tang10% OwnerPurchase249.9K$3.56$891.1K
Jun 30, 2026Alan EzekowitzDirectorSale18.0K$3.65$65.6K
Feb 4, 2026Robert J GouldDirectorSale15.0K$10.87$163.1K
Feb 4, 2026Robert J GouldDirectorSale15.0K$10.72$160.9K
Jan 6, 2026Robert J GouldDirectorSale15.0K$11.87$178.1K
Dec 17, 2025Curtis Gale OltmansChief Legal OfficerSale3.5K$12.92$44.6K
Dec 10, 2025Peter Kolchinsky10% OwnerSale4.2M$13.98$58.4M
Nov 21, 2025Robert J GouldDirectorSale15.0K$11.03$165.5K
May 9, 2025Greg TourangeauPrincipal Accounting OfficerSale498$5.06$2.5K
May 9, 2024Greg TourangeauPrincipal Accounting OfficerSale236$7.76$1.8K
Mar 8, 2024Greg TourangeauVice President, FinanceSale4.9K$11.72$57.2K
Mar 5, 2024Alex SapirPresident & Chief Executive OfficerPurchase43.4K$11.35$492.0K
May 11, 2023Greg TourangeauPrincipal Accounting OfficerSale210$3.31$695.1
Jan 24, 2023Peter Kolchinsky10% OwnerPurchase1.9M$13.00$25.0M
Jan 13, 2023Robert J GouldInterim President & CEOSale6.8K$15.00$101.5K
Jan 6, 2023Peter Kolchinsky10% OwnerPurchase180.7K$7.28$1.3M
Dec 29, 2022Peter Kolchinsky10% OwnerPurchase4.1K$5.99$24.5K
Dec 21, 2022Peter Kolchinsky10% OwnerPurchase98.8K$5.90$582.8K
Dec 16, 2022Peter Kolchinsky10% OwnerPurchase2.4M$5.44$13.1M
Jun 8, 2022Robert J GouldDirectorSale71.4K$8.09$577.9K
Jun 6, 2022Robert J GouldDirectorSale66.6K$8.00$532.8K
Apr 11, 2022Robert J GouldDirectorSale5.6K$24.02$135.2K
Apr 5, 2022Robert J GouldDirectorSale94.3K$24.16$2.3M
Aug 12, 2021Christopher MoxhamChief Scientific OfficerSale51.8K$17.60$911.4K

Showing the 25 most recent of 68 Form 4 filings for Fulcrum Therapeutics, Inc..

Most active FULC insiders

  • Robert J Gould21 filings
  • Diego Cadavid9 filings
  • Owen B. Wallace6 filings
  • Peter G. Thomson6 filings
  • Peter Kolchinsky6 filings

Ask anything about FULC insider activity

Use Trabud's AI agent to query Fulcrum Therapeutics, Inc.'s Form 4 history in plain English — "Show me FULC CEO purchases this year" or compare it against any other ticker.

Open the AI agent

FULC insider trading FAQ

Are Fulcrum Therapeutics, Inc. insiders buying or selling?

Across 68 SEC Form 4 filings, Fulcrum Therapeutics, Inc. (FULC) insiders reported 18 open-market purchases totaling $51.6M and 50 sales totaling $66.7M. That is a net selling position of $15.1M.

How many insiders trade FULC stock?

20 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Fulcrum Therapeutics, Inc.. The most recent filing was accepted on Jul 21, 2026.

Where does Trabud get FULC insider trading data?

All FULC insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.

Looking for another company? Browse all tracked companies.

Related Content